We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions.
- Authors
Rossat, Stéphane; Perrier, Hervé; Lefevre, Marine; Louvet, Christophe; Le Berre, Nathalie; Chamois, Jérôme; Dorel, Maryline; Vacque, Daniel; Guillaudeau, Angélique; Genet, Dominique; Maillet, Evelyne; Triby, Simon; Sabourin, Jean-Christophe
- Abstract
In some situations, there is a need for rapid mutation tests for guiding clinical decisions and starting targeted therapies with minimal delays. In this study we evaluated the turnaround time before and after the implementation of a fully automated multiplex assay for KRAS and NRAS/BRAF mutation tests (Idylla™ platform, Biocartis) in metastatic colorectal cancer. The objective of this project was to compare the turnaround times in 2017–2018 with the fully automated multiplex assay to the 2016 results with previous methods. Centers with a number of tests for metastatic colorectal cancer > 100 yearly and a usual turnaround time ≥ 3 weeks for mutation detection were selected. Results of 505 KRAS tests and 369 NRAS/BRAF tests were transmitted by 10 centers. The mean turnaround time from test prescription to reception of results was reduced from 25.8 days in 2016 to 4.5 days in 2017–2018. In conclusion, this pilot project shows that the Idylla™ platform for testing KRAS and NRAS/BRAF mutations allows an optimized turnaround time from test prescription to reception of results.
- Subjects
TURNAROUND time; COLORECTAL cancer; LONGITUDINAL method; PILOT projects; METASTASIS; HOSPITAL central service departments; MEDICAL center design &; construction
- Publication
Pathology & Oncology Research, 2020, Vol 26, Issue 4, p2469
- ISSN
1219-4956
- Publication type
Article
- DOI
10.1007/s12253-020-00818-y